Sign Up to like & get
recommendations!
0
Published in 2018 at "Advances in Therapy"
DOI: 10.1007/s12325-018-0742-9
Abstract: Tumor necrosis factor (TNF) inhibitors are widely used biologics for the treatment of several chronic inflammatory diseases. The launch of anti-TNF biosimilars has introduced the possibility of non-medical switching between originator biologics and their biosimilars.…
read more here.
Keywords:
medical switching;
evidence;
tumor necrosis;
switching originator ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-214757
Abstract: We read with great interest the recently published results from DANBIO registry on switching from originator etanercept (ETA) to the biosimilar SB4.1 The study includes a really impressive number of patients who underwent mandatory switching…
read more here.
Keywords:
biosimilar sb4;
medical switching;
sb4;
originator etanercept ... See more keywords